Elite Pharmaceuticals unveils generic Hydroxyzine Tablets
M2 - Wed Apr 22, 6:12AM CDT
Pharmaceutical company Elite Pharmaceuticals (OtherOTC:ELTP) revealed on Tuesday the availability of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions.
Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
GlobeNewswire - Tue Apr 21, 9:02AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 123.83 (-0.48), LCI: 52.60 (-0.73), ACT: 296.60 (-0.86), EGLT: 9.39 (-0.11), ZGNX: 1.40 (-0.01), PFE: 33.99 (+0.05), ABBV: 65.99 (+0.02), TEVA: 60.23 (-0.99), ALKS: 60.00 (unch), ACUR: 0.80 (+0.03)
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 123.83 (-0.48), LCI: 52.60 (-0.73), EGLT: 9.39 (-0.11), ACT: 296.60 (-0.86), ZGNX: 1.40 (-0.01), PFE: 33.99 (+0.05), ABBV: 65.99 (+0.02), TEVA: 60.23 (-0.99), ALKS: 60.00 (unch), ACUR: 0.80 (+0.03)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
GlobeNewswire - Thu Feb 12, 1:49PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.37 (+0.05)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 296.60 (-0.86), ZGNX: 1.40 (-0.01), PFE: 33.99 (+0.05)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 9.39 (-0.11), ACT: 296.60 (-0.86), PFE: 33.99 (+0.05), ACUR: 0.80 (+0.03)
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
GlobeNewswire - Thu Jan 15, 9:46AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST
Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"